mechlorethamine hydrochloride

mechlorethamine hydrochloride

[mek′lôreth′əmēn]
an antineoplastic alkylating agent. Also called nitrogen mustard.
indications It is prescribed in the treatment of a variety of neoplasms, especially lymphomas, and of malignant effusions.
contraindications Bone marrow depression, pregnancy, infection, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse effects are bone marrow depression and inflammation caused by extravasation at the site of injection. Nausea, vomiting, and alopecia also may occur.
References in periodicals archive ?
is a privately held, specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage mycosis fungoides, a type of CTCL.
a privately held, specialty pharmaceutical company, announced today that it has resubmitted the New Drug Application (NDA) for its proprietary gel formulation of mechlorethamine hydrochloride (mechlorethamine) to the U.
is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL.
a privately held specialty pharmaceutical company, announced today that the results of a pivotal trial comparing its proprietary gel formulation of mechlorethamine hydrochloride 0.
Yaupon recently submitted a New Drug Application (NDA) to the FDA for a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL).
Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).
New management to focus on NDA submission for proprietary gel formulation of mechlorethamine hydrochloride to treat early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma -